1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Riparian Pharmaceuticals, Inc.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2012

Location

Boston MA US

Primary Industry

Biotechnology

About

Founded in 2012 and based in Massachusetts, US, Riparian Pharmaceuticals, Inc. is a biotechnology company that researches and develops novel therapies using models of pathophysiology, to treat vascular diseases. The company cooperates with Brigham & Women’s Hospital, and the Biotech Community. Mr. Will Adams is the CEO and founder of the company. The company provides vascular health therapeutics for vascular diseases.
Current Investors
Massachusetts Life Sciences Center, Johnson & Johnson Innovation, JMCR Family Office

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.riparianpharma.com
Verticals
Research (Non-Medical)
Company Stage
Series A
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.